Xeris Biopharma Holdings Inc (XERS)

$1.76

-0.02

(-1.12%)

Market is closed - opens 7 PM, 19 Apr 2024

Insights on Xeris Biopharma Holdings Inc

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 48.32M → 44.39M (in $), with an average decrease of 8.1% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, -12.18M → -13.39M (in $), with an average decrease of 9.9% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 48.8% return, outperforming this stock by 70.2%

Performance

  • $1.73
    $1.80
    $1.76
    downward going graph

    1.7%

    Downside

    Day's Volatility :3.7%

    Upside

    2.03%

    downward going graph
  • $1.46
    $3.26
    $1.76
    downward going graph

    17.05%

    Downside

    52 Weeks Volatility :55.21%

    Upside

    46.01%

    downward going graph

Returns

PeriodXeris Biopharma Holdings IncSector (Health Care)Index (Russel 2000)
3 Months
-26.14%
-0.7%
0.0%
6 Months
1.73%
7.7%
0.0%
1 Year
-21.43%
3.3%
-1.7%
3 Years
-3.3%
13.9%
-20.7%

Highlights

Market Capitalization
247.2M
Book Value
- $0.05
Earnings Per Share (EPS)
-0.45
Wall Street Target Price
4.75
Profit Margin
-37.98%
Operating Margin TTM
-22.17%
Return On Assets TTM
-8.25%
Return On Equity TTM
-324.2%
Revenue TTM
163.9M
Revenue Per Share TTM
1.19
Quarterly Revenue Growth YOY
33.900000000000006%
Gross Profit TTM
87.6M
EBITDA
-31.7M
Diluted Eps TTM
-0.45
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.38
EPS Estimate Next Year
-0.22
EPS Estimate Current Quarter
-0.1
EPS Estimate Next Quarter
-0.09

Analyst Recommendation

Buy
    90%Buy
    9%Hold
    0
    0%Sell
Based on 11 Wall street analysts offering stock ratings for Xeris Biopharma Holdings Inc(by analysts ranked 0 to 5 stars)
Based on 11 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
10
10
9
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 169.89%

Current $1.76
Target $4.75

Company Financials

FY18Y/Y Change
Revenue
2.5M
↑ 58.42%
Net Income
-60.1M
↑ 126.26%
Net Profit Margin
-2.4K%
↓ 730.76%
FY19Y/Y Change
Revenue
2.7M
↑ 10.43%
Net Income
-125.6M
↑ 109.02%
Net Profit Margin
-4.6K%
↓ 2176.2%
FY20Y/Y Change
Revenue
20.2M
↑ 640.45%
Net Income
-91.1M
↓ 27.42%
Net Profit Margin
-452.2%
↑ 4161.32%
FY21Y/Y Change
Revenue
49.6M
↑ 146.04%
Net Income
-122.7M
↑ 34.66%
Net Profit Margin
-247.48%
↑ 204.72%
FY22Y/Y Change
Revenue
110.2M
↑ 122.32%
Net Income
-94.7M
↓ 22.87%
Net Profit Margin
-85.86%
↑ 161.62%
FY23Y/Y Change
Revenue
163.9M
↑ 48.68%
Net Income
-62.3M
↓ 34.23%
Net Profit Margin
-37.98%
↑ 47.88%
Q3 FY22Q/Q Change
Revenue
33.2M
↑ 31.18%
Net Income
-26.6M
↑ 1.61%
Net Profit Margin
-80.15%
↑ 23.32%
Q4 FY22Q/Q Change
Revenue
38.0M
↑ 14.5%
Net Income
-19.8M
↓ 25.43%
Net Profit Margin
-52.2%
↑ 27.95%
Q1 FY23Q/Q Change
Revenue
33.2M
↓ 12.66%
Net Income
-16.8M
↓ 15.16%
Net Profit Margin
-50.71%
↑ 1.49%
Q2 FY23Q/Q Change
Revenue
38.0M
↑ 14.5%
Net Income
-19.8M
↑ 17.87%
Net Profit Margin
-52.2%
↓ 1.49%
Q3 FY23Q/Q Change
Revenue
48.3M
↑ 27.13%
Net Income
-12.2M
↓ 38.57%
Net Profit Margin
-25.23%
↑ 26.97%
Q4 FY23Q/Q Change
Revenue
44.4M
↓ 8.13%
Net Income
-13.4M
↑ 9.85%
Net Profit Margin
-30.16%
↓ 4.93%
FY18Y/Y Change
Total Assets
120.0M
↑ 166.74%
Total Liabilities
44.6M
↓ 56.61%
FY19Y/Y Change
Total Assets
109.0M
↓ 9.2%
Total Liabilities
94.6M
↑ 111.89%
FY20Y/Y Change
Total Assets
159.2M
↑ 46.03%
Total Liabilities
125.4M
↑ 32.62%
FY21Y/Y Change
Total Assets
304.4M
↑ 91.24%
Total Liabilities
209.1M
↑ 66.78%
FY22Y/Y Change
Total Assets
344.5M
↑ 13.2%
Total Liabilities
299.3M
↑ 43.13%
FY23Y/Y Change
Total Assets
322.6M
↓ 6.36%
Total Liabilities
329.4M
↑ 10.04%
Q3 FY22Q/Q Change
Total Assets
321.4M
↑ 0.86%
Total Liabilities
291.3M
↑ 19.06%
Q4 FY22Q/Q Change
Total Assets
328.8M
↑ 2.31%
Total Liabilities
315.1M
↑ 8.18%
Q1 FY23Q/Q Change
Total Assets
321.4M
↓ 2.26%
Total Liabilities
291.3M
↓ 7.56%
Q2 FY23Q/Q Change
Total Assets
328.8M
↑ 2.31%
Total Liabilities
315.1M
↑ 8.18%
Q3 FY23Q/Q Change
Total Assets
327.8M
↓ 0.3%
Total Liabilities
323.9M
↑ 2.79%
Q4 FY23Q/Q Change
Total Assets
340.8M
↑ 3.97%
Total Liabilities
347.6M
↑ 7.3%
FY18Y/Y Change
Operating Cash Flow
-56.3M
↑ 128.19%
Investing Cash Flow
-68.3M
↑ 9651.57%
Financing Cash Flow
128.2M
↑ 264.87%
FY19Y/Y Change
Operating Cash Flow
-104.3M
↑ 85.41%
Investing Cash Flow
-2.4M
↓ 96.51%
Financing Cash Flow
80.5M
↓ 37.19%
FY20Y/Y Change
Operating Cash Flow
-80.6M
↓ 22.8%
Investing Cash Flow
-27.4M
↑ 1050.02%
Financing Cash Flow
126.1M
↑ 56.54%
FY21Y/Y Change
Operating Cash Flow
-95.5M
↑ 18.59%
Investing Cash Flow
98.0M
↓ 457.47%
Financing Cash Flow
27.2M
↓ 78.39%
FY22Y/Y Change
Operating Cash Flow
-102.9M
↑ 7.7%
Investing Cash Flow
34.5M
↓ 64.82%
Financing Cash Flow
127.5M
↑ 367.84%
Q3 FY22Q/Q Change
Operating Cash Flow
-26.1M
↑ 26.84%
Investing Cash Flow
6.7M
↓ 43.47%
Financing Cash Flow
-863.0K
↓ 378.39%
Q4 FY22Q/Q Change
Operating Cash Flow
-13.7M
↓ 47.42%
Investing Cash Flow
9.2M
↑ 36.65%
Financing Cash Flow
556.0K
↓ 164.43%
Q1 FY23Q/Q Change
Operating Cash Flow
-26.1M
↑ 90.19%
Investing Cash Flow
8.5M
↓ 7.81%
Financing Cash Flow
-863.0K
↓ 255.22%
Q2 FY23Q/Q Change
Operating Cash Flow
-13.7M
↓ 47.42%
Investing Cash Flow
8.5M
↑ 0.0%
Financing Cash Flow
556.0K
↓ 164.43%
Q3 FY23Q/Q Change
Operating Cash Flow
-14.6M
↑ 6.3%
Investing Cash Flow
14.7M
↑ 73.39%
Financing Cash Flow
-72.0K
↓ 112.95%

Technicals Summary

Sell

Neutral

Buy

Xeris Biopharma Holdings Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Xeris Biopharma Holdings Inc
Xeris Biopharma Holdings Inc
-18.14%
1.73%
-21.43%
-3.3%
-3.3%
Moderna, Inc.
Moderna, Inc.
-2.96%
23.83%
-28.58%
-37.0%
331.65%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-7.23%
10.55%
10.52%
78.91%
167.64%
Novo Nordisk A/s
Novo Nordisk A/s
-6.56%
25.69%
48.76%
237.69%
410.4%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-5.23%
7.86%
19.8%
79.52%
133.49%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Xeris Biopharma Holdings Inc
Xeris Biopharma Holdings Inc
NA
NA
NA
-0.38
-3.24
-0.08
NA
-0.05
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-6.8
-0.29
-0.12
NA
36.27
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
25.71
25.71
1.46
45.13
0.16
0.08
NA
242.47
Novo Nordisk A/s
Novo Nordisk A/s
46.58
46.3
2.4
3.33
0.88
0.23
0.01
23.9
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
28.42
28.42
0.53
16.73
0.23
0.13
NA
68.22
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Xeris Biopharma Holdings Inc
Xeris Biopharma Holdings Inc
Buy
$247.2M
-3.3%
NA
-37.98%
Moderna, Inc.
Moderna, Inc.
Buy
$39.1B
331.65%
24.73
-68.84%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$98.1B
167.64%
25.71
30.14%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$551.2B
410.4%
46.58
36.03%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$101.9B
133.49%
28.42
36.68%

Institutional Holdings

  • BlackRock Inc

    7.13%
  • Vanguard Group Inc

    5.05%
  • Stonepine Capital Management Llc

    4.23%
  • Caxton Corp

    4.02%
  • MPM Oncology Impact Management LP

    2.74%
  • Rosalind Advisors, Inc.

    2.52%

Company Information

xeris aspires to break through this restraint by developing ultra-low volume, ready-to-use biotherapeutics delivered through patient-friendly injectable devices. products built on our xeriject technologies could potentially ease the pain of injections for hundreds of millions of patients.

Organization
Xeris Biopharma Holdings Inc
Employees
377
CEO
Mr. Paul R. Edick
Industry
Health Technology

FAQs